These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 2142921

  • 1. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
    Costantini S, Anserini P, Valenzano M, Remorgida V, Venturini PL, De Cecco L.
    Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
    [Abstract] [Full Text] [Related]

  • 2. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
    West CP, Lumsden MA, Lawson S, Williamson J, Baird DT.
    Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
    [Abstract] [Full Text] [Related]

  • 3. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
    Hackenberg R, Gesenhues T, Deichert U, Duda V, Sturm G, Schulz KD.
    Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study.
    Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT.
    Am J Obstet Gynecol; 1985 Aug 15; 152(8):1034-8. PubMed ID: 3927734
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of goserelin-depot in the clinical management of uterine fibroids.
    Cagnacci A, Paoletti AM, Soldani R, Angiolucci M, Arangino S, Falqui A, Melis GB.
    Clin Exp Obstet Gynecol; 1994 Aug 15; 21(4):263-5. PubMed ID: 7994879
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
    Vollenhoven BJ, Shekleton P, McDonald J, Healy DL.
    Fertil Steril; 1990 Dec 15; 54(6):1032-8. PubMed ID: 2123160
    [Abstract] [Full Text] [Related]

  • 10. Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring leiomyomata.
    Franssen AM, Willemsen WN, Corbey RS, Doesburg WH, van 't Veen AJ, Rolland R.
    Eur J Obstet Gynecol Reprod Biol; 1991 Jul 25; 40(3):221-8. PubMed ID: 1908799
    [Abstract] [Full Text] [Related]

  • 11. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
    West CP, Lumsden MA, Hillier H, Sweeting V, Baird DT.
    Hum Reprod; 1992 Mar 25; 7(3):328-32. PubMed ID: 1534089
    [Abstract] [Full Text] [Related]

  • 12. [Differential effects of GnRH analogs on androgen concentrations in females].
    Wirth U, Rossmanith WG, Sasse V, Lauritzen C.
    Gynakol Rundsch; 1991 Mar 25; 31 Suppl 2():400-2. PubMed ID: 1838737
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography.
    Donnez J, Schrurs B, Gillerot S, Sandow J, Clerckx F.
    Fertil Steril; 1989 Jun 25; 51(6):947-50. PubMed ID: 2498131
    [Abstract] [Full Text] [Related]

  • 14. [New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex].
    Gesenhues T, Hackenberg R, Diechert U, Duda V, Sturm G, Schulz KD.
    Geburtshilfe Frauenheilkd; 1989 Feb 25; 49 Suppl 1():96-8. PubMed ID: 2522904
    [Abstract] [Full Text] [Related]

  • 15. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
    Nakamura Y, Yoshimura Y, Yamada H, Ubukata Y, Ando M, Suzuki M.
    Fertil Steril; 1991 May 25; 55(5):900-5. PubMed ID: 1902420
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
    Matta WH, Shaw RW, Nye M.
    Br J Obstet Gynaecol; 1989 Feb 25; 96(2):200-6. PubMed ID: 2495020
    [Abstract] [Full Text] [Related]

  • 18. Use of GnRH depot analogue in the treatment of uterine fibroids.
    Auber G, Ricci G, Barciulli F, Pregazzi R, D'Ancona RL, Toffoletti FG.
    Acta Eur Fertil; 1990 Feb 25; 21(4):185-9. PubMed ID: 2150737
    [Abstract] [Full Text] [Related]

  • 19. Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist.
    Thomas EJ, Jenkins J, Lenton EA, Cooke ID.
    Br Med J (Clin Res Ed); 1986 Nov 29; 293(6559):1407-8. PubMed ID: 2948607
    [No Abstract] [Full Text] [Related]

  • 20. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas.
    Maheux R, Lemay A, Merat P.
    Fertil Steril; 1987 Feb 29; 47(2):229-33. PubMed ID: 3102282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.